Kyntra Bio (KYNB) Enterprise Value (2014 - 2026)
Kyntra Bio (KYNB) posted Enterprise Value of -$15.5 million for Q1 2026, up 57.35% sequentially from -$36.4 million in Q4 2025, and down 217.0% YoY from $13.3 million in Q1 2025.
Kyntra Bio (KYNB) Enterprise Value (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Enterprise Value for 13 years, with the latest figure at -$15.5 million in Q1 2026.
- Quarterly Enterprise Value fell 217.0% year-over-year to -$15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.5 million (down 217.0% YoY) and the FY2025 annual result came in at -$36.4 million, up 54.92% from the prior year.
- Enterprise Value improved to -$15.5 million in Q1 2026 per KYNB's latest filing, from -$36.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at $13.3 million in Q1 2025 and troughed at -$422.0 million in Q4 2022.
- A 5-year average of -$179.7 million and a median of -$109.5 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 114.46% in 2025, then slumped 217.0% in 2026.
- Over 5 years, Enterprise Value stood at -$422.0 million in 2022, then surged by 49.26% to -$214.1 million in 2023, then soared by 62.31% to -$80.7 million in 2024, then surged by 54.92% to -$36.4 million in 2025, then surged by 57.35% to -$15.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$15.5 million, -$36.4 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 2.12 Bn |
| 10 | Kyntra Bio | 30.36 Mn | 30.36 Mn | 1.47 Mn | -69.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.84 Mn |
| Mar 31, 2026 | -15.52 Mn |
| Dec 31, 2025 | -36.38 Mn |
| Sep 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | -6.37 Mn |
| Mar 31, 2025 | 13.26 Mn |
| Dec 31, 2024 | -80.70 Mn |
| Sep 30, 2024 | -109.52 Mn |
| Jun 30, 2024 | -119.23 Mn |
| Mar 31, 2024 | -91.72 Mn |
| Dec 31, 2023 | -214.11 Mn |
| Sep 30, 2023 | -104.41 Mn |
| Jun 30, 2023 | -314.24 Mn |
| Mar 31, 2023 | -335.98 Mn |
| Dec 31, 2022 | -422.01 Mn |
| Sep 30, 2022 | -388.55 Mn |
| Jun 30, 2022 | -418.17 Mn |
| Mar 31, 2022 | -408.11 Mn |
| Dec 31, 2021 | -385.22 Mn |
| Sep 30, 2021 | -467.13 Mn |